Form 4: BioCryst CEO Gifts Shares to Family Trusts

BioCryst Pharmaceuticals CEO Jon Stonehouse gifted 20,000 shares of common stock to two irrevocable family trusts on December 18, 2025.

Summary

• Jon Stonehouse, Chief Executive Officer and Director of BioCryst Pharmaceuticals Inc. (BCRX), reported changes in his beneficial ownership.
• On December 18, 2025, Stonehouse gifted 10,000 shares of common stock, held directly by him, to the Caroline Stonehouse Irrevocable Trust.
• On the same date, he gifted an additional 10,000 shares of common stock, also held directly by him, to the Samuel Stonehouse Irrevocable Trust.
• These transactions resulted in a direct disposition of 20,000 shares of common stock by Jon Stonehouse.
• Following these gifts, Jon Stonehouse directly beneficially owns 1,385,222 shares of common stock.
• His wife, as co-trustee, indirectly beneficially owns 40,000 shares in the Caroline Stonehouse Irrevocable Trust and 40,000 shares in the Samuel Stonehouse Irrevocable Trust.
• The filing also includes a Power of Attorney, dated June 11, 2025, authorizing Alane P. Barnes and Sara A. Mykrantz to prepare and file SEC reports (Forms ID, 3, 4, and 5) on Stonehouse's behalf.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock gift for estate planning purposes, which is a neutral event regarding company performance or outlook.

Positives

• Insider ownership remains substantial, with Jon Stonehouse directly holding 1,385,222 shares after the gifts, indicating continued alignment of interests.
• The shares remain within the family's beneficial ownership through the irrevocable trusts.

Negatives

• Jon Stonehouse directly disposed of 20,000 shares of common stock through gifts, reducing his direct holdings.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Jon Stonehouse, CEO, gifted 10,000 shares to the Caroline Stonehouse Irrevocable Trust and 10,000 shares to the Samuel Stonehouse Irrevocable Trust, where his wife serves as a co-trustee.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership by the CEO, though beneficial ownership remains within family trusts, which typically does not significantly impact company valuation or share price.

Key Dates

Recommendation

This filing details a routine insider stock gift for estate planning purposes by the CEO. It does not provide any new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is neutral for the company's valuation, and therefore, a 'hold' recommendation is maintained based solely on this filing.

Keywords

BioCryst Pharmaceuticals, BCRX, Jon Stonehouse, insider transaction, Form 4, beneficial ownership, stock gift, CEO, director